Michael Coyle

Michael Coyle

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
SCSophie R. Cohen
Sophie R. Cohen
MTMichelle L. Terry
Michelle L. Terry
MCMichael Coyle
Michael Coyle
EWEmily Wheelis
Emily Wheelis
ACAshley Centner
Ashley Centner
CBChristopher Bishop
Christopher Bishop

8 March 2023 in Cells
Verified
Journal Article
Open access
PDF file
CBCarla N Budrow
Carla N Budrow
KEKayla Elder
Kayla Elder
MCMichael Coyle
Michael Coyle
ACAshley Centner
Ashley Centner
NLNatalie Lipari
Natalie Lipari
CBChristopher Bishop
Christopher Bishop
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by motor symptoms that result from loss of nigrostriatal dopamine (DA) cells. While L-DOPA provides symptom alleviation, its chronic use often results in the development of L-DOPA-induced dyskinesia (LID). Evidence suggests that neuroplasticity within the serotonin (5-HT) system contributes to LID onset, persistence, and severity. This has been supported by research showing 5-HT compounds targeting 5-HT1A/1B receptors and/or the 5-HT transporter (SERT) can reduce LID. Recently, vortioxetine, a multimodal 5-HT compound developed for depression, demonstrated acute anti-dyskinetic effects. However, the durability and underlying pharmacology of vortioxetine’s anti-dyskinetic actions have yet to be delineated. To address these gaps, we used hemiparkinsonian rats in Experiment 1, examining the effects of sub-chronic vortioxetine on established LID and motor performance. In Experiment 2, we applied the 5-HT1A antagonist WAY-100635 or 5-HT1B antagonist SB-224289 in conjunction with L-DOPA and vortioxetine to determine the contributions of each receptor to vortioxetine’s effects. The results revealed that vortioxetine consistently and dose-dependently attenuated LID while independently, 5-HT1A and 5-HT1B receptors each partially reversed vortioxetine’s effects. Such findings further support the promise of pharmacological strategies, such as vortioxetine, and indicate that broad 5-HT actions may provide durable responses without significant side effects.

20 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NCNicole E. Chambers
Nicole E. Chambers
AMAnnique McLune
Annique McLune
MCMichael Coyle
Michael Coyle
ACAshley Centner
Ashley Centner
JSJordan Sergio
Jordan Sergio
CBChristopher Bishop
Christopher Bishop
Standard treatment for Parkinson’s disease (PD) is dopamine replacement therapy with L-DOPA. However, chronic treatment often results in abnormal involuntary movements called L-DOPA-induced dyskinesia (LID). Prior evidence indicates that heightened striatal cholinergic tone may contribute to LID. Restoring cholinergic inhibition by targeting the inhibitory M 4 muscarinic acetylcholine (ACh) receptor (M 4 ) reduces LID in preclinical models. Although intrinsic striatal sources of ACh have been considered for their role in LID, extrinsic sources of ACh such as the pedunculopontine nucleus (PPN) have not been well investigated for their role in LID. Therefore, the current study employed hemiparkinsonian Long-Evans rats with a PPN-targeted cannula ipsilateral to 6-OHDA lesion. Following chronic treatment with L-DOPA, we examined the effect of local unilateral PPN infusion of M 4 PAM VU0467154 on LID, motor performance, and c-fos expression within the PPN. It was expected that PPN infusion of VU0467154 would reduce LID, reduce L-DOPA’s motor benefit, and globally reduce c-fos expression in the PPN. Contrary to our expectations, PPN infusion of M 4 PAM did not significantly affect LID severity. Furthermore, the group receiving M 4 PAM showed slightly elevated motor improvement compared to L-DOPA, and decreased c-fos expression specifically in PPN cholinergic neurons. These results suggest that local PPN ACh dynamics differ from those of the striatum. Specifically, our results suggest that PPN cholinergic neurons may be a promising therapeutic target for augmenting L-DOPA-mediated motor benefit without increasing LID.

25 September 2025 in Behavioural Brain Research
Verified
Journal Article
Closed access
NCNicole E. Chambers
Nicole E. Chambers
AMAnnique McLune
Annique McLune
MCMichael Coyle
Michael Coyle
ACAshley Centner
Ashley Centner
JSJordan Sergio
Jordan Sergio
CBChristopher Bishop
Christopher Bishop